4005.SR4005.SRSAU
Loading
National Medical Care Company operates a network of private healthcare facilities across Saudi Arabia, including hospitals, clinics, and specialized medical centers. The company benefits from Saudi Vision 2030's healthcare privatization initiatives and growing domestic healthcare demand driven by population growth and rising chronic disease prevalence. With a 3.90x current ratio and 0.24x debt/equity, the balance sheet provides significant financial flexibility for expansion.
Generates revenue through fee-for-service model with mix of government insurance reimbursements (mandatory health insurance coverage), corporate contracts, and direct patient payments. Pricing power stems from brand reputation, accreditation standards, and limited high-quality private healthcare capacity in key Saudi markets. 36.8% gross margin reflects labor-intensive model with physician salaries, nursing staff, and medical supplies as primary costs. Operating leverage improves with bed utilization rates and procedure volumes.
New facility openings and bed capacity additions - expansion into underserved Saudi regions
Government healthcare policy changes - mandatory insurance coverage expansion, reimbursement rate adjustments
Occupancy rates and revenue per available bed (RevPAB) trends across existing facilities
Medical tourism initiatives and cross-border patient volumes from GCC countries
Physician recruitment and retention - ability to attract specialized talent affects service mix and pricing
Regulatory risk from government healthcare pricing controls or reimbursement rate reductions to contain national healthcare costs
Workforce dependency on expatriate physicians and nurses - visa policy changes or regional competition for medical talent could increase labor costs
Technology disruption from telemedicine platforms reducing outpatient visit volumes, though surgical/inpatient services remain protected
Intensifying competition from international hospital chains entering Saudi market (Cleveland Clinic, Mayo Clinic partnerships) with superior brand recognition
Public hospital quality improvements under Vision 2030 reducing private sector market share for basic services
Pricing pressure from insurance companies consolidating purchasing power and negotiating lower reimbursement rates
Minimal near-term financial risk given 0.24x debt/equity and strong liquidity, but aggressive expansion could strain cash flows
Capex intensity risk - $100M annual capex against $200M operating cash flow leaves limited FCF cushion ($4M TTM) for dividends or opportunistic M&A
low-to-moderate - Healthcare demand is relatively inelastic as medical needs persist across economic cycles. However, elective procedures and premium services show some sensitivity to consumer confidence and corporate health benefit budgets. Saudi government healthcare spending (linked to oil revenues) affects insurance reimbursement rates and public-private partnership opportunities. 23.7% revenue growth suggests strong structural demand tailwinds from demographics and healthcare infrastructure investment.
Rising rates have moderate negative impact through two channels: (1) Higher financing costs for expansion capex, though 0.24x debt/equity suggests minimal current leverage; (2) Valuation multiple compression as healthcare facilities trade on yield-like characteristics (stable cash flows). Saudi Arabia's currency peg to USD means SAMA typically follows Fed rate policy. However, strong 19.9% net margin and $200M operating cash flow provide internal funding capacity.
Moderate exposure to credit conditions through insurance reimbursement cycles and corporate contract renewals. Tighter credit conditions could pressure DSO if insurance companies delay payments or employers reduce health benefit coverage. 3.90x current ratio provides substantial liquidity buffer. Government-backed mandatory insurance program reduces bad debt risk compared to purely private-pay models.
growth - 23.7% revenue growth and Vision 2030 healthcare privatization theme attract growth investors seeking exposure to Saudi demographic trends and healthcare infrastructure buildout. However, recent 25% one-year decline and low 0.4% FCF yield suggest momentum investors have exited. 18.6% ROE appeals to quality-focused investors, but high 3.6x P/S and 13.0x EV/EBITDA require continued execution on expansion pipeline.
moderate-to-high - Recent 26.7% six-month decline indicates elevated volatility, likely driven by Saudi market beta, healthcare sector rotation, and execution concerns around capex deployment. Healthcare facilities typically exhibit lower volatility than broader market, but emerging market exposure and growth stock valuation (3.2x P/B) amplify price swings during risk-off periods.